Infectious Disease

Dr Hatfield shares a case of a patient living in shared housing who was concerned about her housemates seeing her PrEP medication.

Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

WHO experts weighed decades of high-quality studies against flawed analyses, finding consistent evidence that current vaccines pose no autism-related risk.

The inquiry follows internal requests for closer review of trial findings and real-world evidence; regulators have not yet indicated any planned actions.

A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.

Formulary restrictions and prior authorization requirements block access to newer PrEP options, while cost sharing over $50 cuts dispensing odds by 93%.

Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.

The H3N2 subclade K is dominating early flu season gobally; despite vaccine mismatch, vaccination remains the primary defense against severe illness and hospitalization.

Two new Cochrane reviews confirm HPV vaccines significantly reduce cervical cancer risk, especially when given before age 16, with no serious safety concerns.

The CDC website now claims "studies supporting a link [between vaccines and autism] have been ignored by health authorities."

Results showed that Pfizer’s mRNA vaccine cut influenza-like illness by 34.5% compared with a standard influenza vaccine.

Your daily dose of the clinical news you may have missed.

Vaccine-preventable diseases claim up to 50,000 adult lives each year in the US. Click through this compact reminder of recommended catch up shots for your patient panel.

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

Shared decision-making for COVID-19 vaccines will widen disparities, said Moore, as those already skeptical or with limited access will likely opt out.

New global WHO data show escalating resistance in key bacterial pathogens, threatening frontline antibiotics and narrowing treatment options worldwide.

Vega considers the impact of recent changes in immunization policy on trust not just among patients but among clinicians as well. It all threatens good patient care, he said.

Public health expert Kelly Moore, MD, MPH, president and CEO of immunize.org, says the news is good for now, but the uninsured could be at future risk.

Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.

Public health officials across states and regions are "thinking on their feet" about how best to protect public health given the upheavel in federal vaccine policy, Moore said.

Vaccines for respiratory syncytial virus were found both safe and effective across 100,000 participants and, critically, for older adults and infants.

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.

Moore, a past voting member of the ACIP, is unsure how the CDC will respond to adding "speculative concerns" to a piece of information given to every person who recieves a vaccine.

Moore, president and CEO of immunize.org, has deep roots in public health and advocacy, vaccine program implementation, and immunization education.